MRUS - Merus NV Stock Price, Fair Value and News

44.79USD-1.06 (-2.31%)Market Closed

Market Summary

USD44.79-1.06

Market Closed

-2.31%

MRUS Alerts

Big fall in Revenue (Y/Y)

Losses in recent quarter

MRUS Stock Price

View Fullscreen

MRUS RSI Chart

MRUS Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-17.98

Price/Sales (Trailing)

70.19

EV/EBITDA

-17.62

Price/Free Cashflow

-17.91

MRUS Price/Sales (Trailing)

MRUS Profitability

EBT Margin

-377.98%

Return on Equity

-42.83%

Return on Assets

-30.05%

Free Cashflow Yield

-5.58%

MRUS Fundamentals

MRUS Revenue

Revenue (TTM)

38.3M

Rev. Growth (Yr)

-41.56%

Rev. Growth (Qtr)

-11.75%

MRUS Earnings

Earnings (TTM)

-149.7M

Earnings Growth (Yr)

13.3%

Earnings Growth (Qtr)

42.72%

Breaking Down MRUS Revenue

Last 7 days

-3.1%

Last 30 days

9.6%

Last 90 days

9.1%

Trailing 12 Months

128.2%

How does MRUS drawdown profile look like?

MRUS Financial Health

Current Ratio

5.23

MRUS Investor Care

Shares Dilution (1Y)

26.13%

Diluted EPS (TTM)

-2.75

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	38.3M	0	0	0
2023	43.4M	41.2M	45.7M	43.9M
2022	52.4M	52.7M	45.6M	41.6M
2021	32.0M	38.3M	43.4M	49.1M
2020	28.6M	28.3M	28.7M	29.9M
2019	36.6M	34.8M	32.9M	31.1M
2018	26.0M	30.1M	34.3M	38.4M
2017	7.4M	12.2M	17.1M	21.9M
2016	0	0	0	2.5M
2015	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Merus NV

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 19, 2023	shuman harry	sold	-3,068	26.68	-115	vp controller, pao
Dec 15, 2023	silverman peter b.	acquired	-	-	22,386	coo & gc
Dec 15, 2023	silverman peter b.	sold	-559,650	25.00	-22,386	coo & gc
Dec 08, 2023	shuman harry	sold	-6,110	24.44	-250	vp controller, pao
Dec 01, 2023	shuman harry	acquired	-	-	2,500	vp controller, pao
Dec 01, 2023	shuman harry	sold	-14,133	24.58	-575	vp controller, pao
Jun 01, 2023	shuman harry	acquired	-	-	2,500	vp controller, pao
Jun 01, 2023	shuman harry	sold	-12,351	21.48	-575	vp controller, pao
Apr 14, 2023	iwicki mark t	acquired	534,679	7.26703	73,576	-
Apr 06, 2023	liu hui	acquired	770,948	7.86	98,085	evp, cbo & head of merus us

Which funds bought or sold MRUS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	FRANKLIN RESOURCES INC	reduced	-0.52	32,567,300	84,352,300	0.03%
May 13, 2024	Balyasny Asset Management L.P.	sold off	-100	-33,914,000	-	-%
May 13, 2024	XTX Topco Ltd	new	-	325,792	325,792	0.04%
May 13, 2024	FMR LLC	added	127	54,776,900	74,864,400	-%
May 13, 2024	Nuveen Asset Management, LLC	added	6.63	896,109	2,097,230	-%
May 13, 2024	UBS Group AG	added	28.53	168,981	321,964	-%
May 13, 2024	HRT FINANCIAL LP	reduced	-67.21	-481,000	557,000	-%
May 13, 2024	NEOS Investment Management LLC	new	-	333,762	333,762	0.02%
May 13, 2024	FIRST TRUST ADVISORS LP	added	45.13	1,331,780	2,299,360	-%
May 13, 2024	PLATINUM INVESTMENT MANAGEMENT LTD	reduced	-29.95	574,237	4,480,040	0.18%

Are Funds Buying or Selling MRUS?

Are funds buying MRUS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRUS

No. of Funds

Unveiling Merus NV's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 25, 2024	incyte corp	6.9%	4,004,544	SC 13G
Mar 06, 2024	federated hermes, inc.	3.98%	2,297,700	SC 13G/A
Feb 14, 2024	commodore capital lp	8.2%	4,747,373	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	2.5%	1,467,604	SC 13G/A
Feb 14, 2024	samlyn capital, llc	5.9%	3,412,410	SC 13G
Feb 12, 2024	flynn james e	5.23%	3,019,901	SC 13G/A
Feb 08, 2024	wellington management group llp	3.48%	2,009,403	SC 13G/A
Jan 18, 2024	federated hermes, inc.	6.30%	3,637,309	SC 13G/A
Aug 14, 2023	incyte corp	6.9%	4,004,544	SC 13D/A
Mar 10, 2023	federated hermes, inc.	4.62%	2,138,700	SC 13G/A

Recent SEC filings of Merus NV

View All Filings

Date Filed	Form Type	Document
May 10, 2024	8-K/A	Current Report
May 09, 2024	3	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading
May 09, 2024	4	Insider Trading

Peers (Alternatives to Merus NV)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	19.54%	-2.80%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	0.98%	-26.98%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-12.72%	-14.31%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	6.98%	-11.75%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	6.22%	110.41%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-16.95%	-51.10%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	9.36%	-4.29%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-10.69%	-43.90%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	206.31%	55.15%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	5.07%	336.18%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.08%	29.79%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-10.40%	79.21%	-0.7	7.61	-13.45%	69.54%

Merus NV News

Latest updates

Merus NV Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-11.7%	7,889,000	8,939,000	11,033,000	10,476,000	13,499,000	10,666,000	6,581,000	12,684,000	11,655,000	14,709,000	13,669,000	12,379,000	8,350,000	9,016,000	8,570,000	6,056,000	6,301,000	7,792,000	8,155,000	6,357,000	8,829,000
Operating Expenses	-3.2%	54,698,000	56,481,000	49,401,000	44,361,000	50,251,000	64,329,000	54,776,000	43,791,000	38,728,000	37,574,000	36,189,000	35,181,000	30,139,000	31,526,000	26,674,000	21,752,000	25,869,000	30,733,000	21,535,000	18,982,000	18,540,000
S&GA Expenses	-100.0%	-	15,796,000	12,591,000	16,063,000	15,386,000	15,283,000	12,469,000	12,695,000	11,753,000	10,823,000	10,171,000	10,569,000	9,333,000	9,720,000	9,136,000	8,043,000	8,882,000	11,131,000	8,024,000	8,214,000	6,741,000
R&D Expenses	-5.2%	38,584,000	40,685,000	36,810,000	28,298,000	34,865,000	49,046,000	42,307,000	31,096,000	26,975,000	26,751,000	26,018,000	24,612,000	20,806,000	21,806,000	17,538,000	13,709,000	16,987,000	19,602,000	13,511,000	10,768,000	11,799,000
EBITDA Margin	-9.4%	-3.72	-3.40	-3.77	-4.25	-3.46	-3.11	-1.36	-0.99	-1.41	-1.33	-1.81	-2.27	-2.42	-2.80	-2.84	-	-	-	-	-	-
Income Taxes	5.9%	1,098,000	1,037,000	1,118,000	1,494,000	-457,000	387,000	327,000	131,000	114,000	139,000	-11,000	62,000	49,000	198,000	177,000	31,000	97,000	-45,000	-54,000	71,000	222,000
Earnings Before Taxes	43.6%	-33,358,000	-59,116,000	-21,894,000	-30,539,000	-40,198,000	-81,585,000	-24,288,000	-5,583,000	-18,779,000	-14,282,000	-14,864,000	-27,326,000	-10,105,000	-27,766,000	-22,898,000	-17,943,000	-16,403,000	-25,471,000	-9,321,000	-13,304,000	-6,861,000
EBT Margin	-9.5%	-3.78	-3.45	-3.81	-4.28	-3.49	-3.13	-1.38	-1.02	-1.44	-1.36	-1.84	-2.30	-2.46	-2.84	-2.88	-	-	-	-	-	-
Net Income	42.7%	-34,456,000	-60,153,000	-23,012,000	-32,033,000	-39,741,000	-81,972,000	-24,615,000	-5,714,000	-18,893,000	-14,421,000	-14,853,000	-27,388,000	-10,154,000	-27,964,000	-23,075,000	-17,974,000	-16,500,000	-25,426,000	-9,267,000	-13,375,000	-7,083,000
Net Income Margin	-10.7%	-3.90	-3.53	-3.87	-4.33	-3.50	-3.15	-1.39	-1.02	-1.44	-1.36	-1.85	-2.31	-2.47	-2.86	-2.89	-	-	-	-	-	-
Free Cashflow	-22.4%	-44,451,000	-36,322,000	-27,569,000	-41,935,000	-40,363,000	-32,568,000	-43,587,000	-34,592,000	-46,739,000	-31,931,000	-23,352,000	-24,400,000	19,186,000	-24,765,000	-12,043,000	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	9.4%	498	455	492	364	339	377	415	445	418	457	356	380	398	231	213	224	238	263	232	201	227
Current Assets	11.2%	410	369	405	283	258	306	368	399	380	424	320	367	386	218	201	211	225	247	-	177	-
Cash Equivalents	-12.4%	179	204	242	101	103	148	191	214	195	241	159	311	327	163	139	152	166	198	134	150	157
Net PPE	-6.6%	11.00	12.00	12.00	13.00	13.00	12.00	7.00	6.00	4.00	4.00	3.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	-	3.00	-
Liabilities	49.9%	149	99.00	99.00	106	121	129	116	118	120	140	150	160	161	129	129	123	123	132	128	124	136
Current Liabilities	13.6%	78.00	69.00	64.00	66.00	75.00	79.00	64.00	60.00	62.00	72.00	72.00	64.00	53.00	47.00	45.00	38.00	36.00	37.00	-	30.00	-
Shareholder's Equity	-1.9%	349	356	393	257	218	247	299	327	297	316	206	219	237	102	85.00	100	115	131	77.00	88.00	98.00
Retained Earnings	-4.6%	-787	-753	-692	-669	-637	-598	-516	-491	-485	-466	-452	-437	-410	-400	-372	-349	-331	-314	-	-190	-
Additional Paid-In Capital	3.1%	1,161	1,126	1,118	949	877	871	865	849	794	788	657	650	643	490	449	446	444	441	-	-	-
Shares Outstanding	1.5%	59.00	58.00	58.00	50.00	46.00	46.00	-	43,781	43,490	-	-	-	36.00	-	-	-	-	29.00	23.00	23.00	-
Float	-	-	-	-	1,304	-	-	-	1,034	-	-	-	730	-	-	-	465	-	-	-	343	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-22.1%	-44,388	-36,348	-27,530	-41,586	-36,743	-30,512	-41,256	-31,734	-46,397	-31,598	-23,075	-24,297	19,343	-24,336	-11,697	-18,608	-25,260	-19,744	-14,024	-15,770	-13,510
Share Based Compensation	-28.5%	4,793	6,708	7,315	6,453	5,750	6,014	6,525	6,662	5,334	4,801	4,331	4,559	3,400	3,045	2,844	1,192	2,291	2,646	2,068	1,860	1,260
Cashflow From Investing	-470.6%	-12,079	-2,117	8,022	-24,518	-8,407	856	-1,141	4,054	-967	-15,759	-133,917	5,727	-2,674	5,900	-6,108	2,710	-3,988	4,148	4,455	7,714	7,855
Cashflow From Financing	1910.4%	30,156	1,500	162,402	65,967	217	-215	9,876	48,199	879	127,042	2,595	1,861	150,457	38,769	22.00	291	438	74,184	17.00	3.00	28.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	285	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MRUS Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total revenue	$ 7,889	$ 13,499
Operating expenses:
Research and development	38,584	34,865
General and administrative	16,114	15,386
Total operating expenses	54,698	50,251
Operating loss	(46,809)	(36,752)
Other income, net:
Interest income, net	4,917	1,995
Foreign exchange gains (loss)	8,534	(5,441)
Total other income (loss), net	13,451	(3,446)
Net loss before income taxes	(33,358)	(40,198)
Income tax expense	1,098	(457)
Net loss	(34,456)	(39,741)
Other comprehensive loss:
Currency translation adjustment	(7,388)	4,242
Comprehensive loss	$ (41,844)	$ (35,499)
Net loss per share attributable to common stockholders:
Basic	$ (0.59)	$ (0.86)
Diluted	$ (0.59)	$ (0.86)
Weighted-average common shares outstanding:
Basic	58,085,416	46,323,772
Diluted	58,085,416	46,323,772
Collaboration Revenue [Member]
Total revenue from contracts with customers	$ 7,889	$ 13,499

MRUS Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 178,168	$ 204,246
Marketable securities	159,328	150,130
Accounts receivable	58,726	2,429
Prepaid expenses and other current assets	14,038	12,009
Total current assets	410,260	368,814
Marketable securities	61,167	57,312
Property and equipment, net	11,336	12,135
Operating lease right-of-use assets	10,767	11,362
Intangible assets, net	1,716	1,800
Deferred tax assets	277	1,199
Other assets	2,560	2,872
Total assets	498,083	455,494
Current liabilities:
Accounts payable	7,488	4,602
Accrued expenses and other liabilities	33,361	38,482
Income taxes payable	1,822	1,646
Current portion of lease obligation	1,674	1,674
Current portion of deferred revenue	34,142	22,685
Total current liabilities	78,487	69,089
Lease obligation	9,853	10,488
Deferred revenue, net of current portion	60,295	19,574
Total liabilities	148,635	99,151
Commitments and contingencies - Note 6
Shareholders' equity:
Common shares, EUR 0.09 par value; 67,500,000 shares authorized at March 31, 2024 and December 31, 2023; 58,687,551 and 57,825,879 shares issued and outstanding as at March 31, 2024 and December 31, 2023, respectively	5,968	5,883
Additional paid-in capital	1,160,918	1,126,054
Accumulated other comprehensive income	(29,921)	(22,533)
Accumulated deficit	(787,517)	(753,061)
Total shareholders' equity	349,448	356,343
Total liabilities and shareholders' equity	$ 498,083	$ 455,494

About Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

CEO	Dr. Sven Ante Lundberg M.D.
WEBSITE	merus.nl
INDUSTRY	Biotechnology
EMPLOYEES	164

Merus NV Frequently Asked Questions

What is the ticker symbol for Merus NV? What does MRUS stand for in stocks?

MRUS is the stock ticker symbol of Merus NV. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Merus NV (MRUS)?

As of Mon May 13 2024, market cap of Merus NV is 2.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRUS stock?

You can check MRUS's fair value in chart for subscribers.

What is the fair value of MRUS stock?

You can check MRUS's fair value in chart for subscribers. The fair value of Merus NV is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Merus NV is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRUS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Merus NV a good stock to buy?

The fair value guage provides a quick view whether MRUS is over valued or under valued. Whether Merus NV is cheap or expensive depends on the assumptions which impact Merus NV's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRUS.

What is Merus NV's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, MRUS's PE ratio (Price to Earnings) is -17.98 and Price to Sales (PS) ratio is 70.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRUS PE ratio will change depending on the future growth rate expectations of investors.